Long-term weight loss with sibutramine: a randomized controlled trial

Area of Science:

• Pharmacology
• Obesity Medicine
• Clinical Trials

Background:

• Obesity treatment necessitates long-term patient adherence, which is often challenging.
• Sibutramine hydrochloride has demonstrated efficacy in obesity management through randomized controlled trials.

Purpose of the Study:

• To compare the weight reduction effectiveness of two distinct sibutramine regimens against a placebo in obese individuals.
• To assess the therapeutic equivalence and safety profiles of continuous versus intermittent sibutramine administration.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving 1102 obese adults (BMI 30-40 kg/m²).
• Participants underwent an initial 4-week open-label sibutramine run-in period.
• Randomized treatment involved 48 weeks of continuous sibutramine, intermittent sibutramine, or placebo.

Main Results:

• Continuous sibutramine therapy resulted in a mean weight loss of 3.8 kg (4.0%), and intermittent therapy in 3.3 kg (3.5%), compared to a 0.2 kg gain with placebo.
• Both sibutramine regimens demonstrated therapeutic equivalence, with no significant difference between continuous and intermittent dosing (P=.28).
• Sibutramine positively impacted waist circumference, triglyceride levels, and HDL cholesterol, with stable blood pressure and comparable adverse event rates across groups.

Conclusions:

• Sibutramine administration for 48 weeks leads to clinically significant weight loss in obese patients compared to placebo.
• Continuous and intermittent sibutramine therapies are therapeutically equivalent in effectiveness.
• The safety profiles of both continuous and intermittent sibutramine treatments are comparable.